Immunotoxicity Testing Services

Immunotoxicity covers two opposite failure modes. A compound may suppress immune function, leaving an animal or patient less able to respond to infection or to control malignancy. Or it may stimulate it inappropriately, producing autoimmunity, hypersensitivity, or cytokine-mediated toxicity. Both are relevant, and a program that evaluates only one has assessed half the risk.

Standard toxicology endpoints detect immunotoxicity poorly. Lymphoid organ weight and histology identify gross changes, but functional suppression frequently occurs without structural change, and a compound can substantially impair immune function while leaving spleen weight and thymic histology unremarkable.

Altogen Labs supports immunotoxicity assessment through immune cell population analysis, lymphoid tissue evaluation, and cytokine profiling, with scope defined per program. To discuss an assessment for a specific compound, request a quote.

What is assessed

Flow cytometric immunophenotyping quantifies immune cell populations in blood, spleen, and other lymphoid tissue, identifying selective depletion or expansion of a subset that a total white cell count would not reveal. The differential composition is frequently more informative than the total, since a normal count can conceal a substantial shift between subsets.

Histopathological evaluation of spleen, thymus, lymph nodes, and bone marrow assesses cellularity and architecture in the compartments where immune cells develop and reside, with findings graded against a defined scale and compared with concurrent controls rather than with published norms.

Cytokine profiling characterizes soluble mediator changes, which is the primary readout where the concern is inappropriate activation rather than suppression.

Relevance by modality

The nature of the concern differs by compound class, and the assessment should follow it. For cytotoxic agents the question is usually suppression, particularly myelosuppression and its consequences. For immunotherapeutics the question is more often inappropriate activation, and for T-cell engaging agents specifically it is cytokine release, which requires a model containing human immune cells capable of producing it.

For biologics, immunogenicity is a distinct consideration from immunotoxicity, since an immune response directed at the therapeutic itself affects exposure and efficacy rather than constituting a toxicity in the conventional sense.

Applied examples

Selective subset depletion. Flow cytometric phenotyping across a repeat-dose study identifies reduction of a specific lymphocyte subset at the top dose while total white cell count remains within the control range.

Lymphoid architecture. Spleen and thymus from treated and control animals are assessed histologically for cellularity and architecture, with graded findings establishing whether a change in organ weight has a structural correlate.

Activation rather than suppression. An immunotherapeutic is assessed for cytokine elevation and immune population expansion, with sampling timed to the expected kinetics of activation rather than to a standard toxicology schedule.

Scope of claims

Altogen Labs describes the immunotoxicity assessment it supports rather than claiming that every immunotoxicology assay named in regulatory guidance is performed. Where a program requires a functional assay outside the available scope, that is identified at the planning stage so the overall package can be completed appropriately.

Conduct and reporting

Panel composition, tissue list, sampling schedule, and comparison basis are defined before initiation, with concurrent controls handled and sampled identically, since immune parameters are sensitive to husbandry, handling stress, and sampling conditions and a difference introduced by any of those is indistinguishable from a treatment effect at analysis. Reports state per-animal values alongside group summaries, since a group mean can conceal an individual finding that is the most important result in the study. All procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.

Send compound class, mechanism, and the immune concern to be addressed, or request a quote.